Results 61 to 70 of about 59,932 (250)

Cardiovascular events and safety outcomes associated with remdesivir using a World Health Organization international pharmacovigilance database

Clinical and Translational Science, 2022
On October 2020, the US Food and Drug Administration (FDA) approved remdesivir as the first drug for the treatment of coronavirus disease 2019 (COVID‐19), increasing remdesivir prescriptions worldwide.
Se Yong Jung, Min Seo Kim, Han Li, Keum Hwa Lee, Ai Koyanagi, Marco Solmi, Andreas Kronbichler, Elena Dragioti, Kalthoum Tizaoui, Sarah Cargnin, Salvatore Terrazzino, Sung Hwi Hong, Ramy Abou Ghayda, Nam Kyun Kim, Seo Kyoung Chung, Louis Jacob, Joe‐Elie Salem, Dong Keon Yon, Seung Won Lee, Karel Kostev, Ah Young Kim, Jo Won Jung, Jae Young Choi, Jin Soo Shin, Soon‐Jung Park, Seong Woo Choi, Kiwon Ban, Sung‐Hwan Moon, Yun Young Go, Jae Il Shin, Lee Smith   +30 more
doaj   +1 more source

Is Low Alveolar Type II Cell SOD3 in the Lungs of Elderly Linked to the Observed Severity of COVID-19? [PDF]

, 2020
Human lungs single cell RNA sequencing data from healthy donors (elderly and young; GEO accession number GSE122960) were analyzed to isolate and specifically study gene expression in alveolar type II cells.
Abouhashem, Ahmed S., Azzazy, Hassan M. E., Sen, Chandan K., Singh, Kanhaiya   +3 more
core   +1 more source

Pharmacogenetic variants and risk of remdesivir-associated liver enzyme elevations in Million Veteran Program participants hospitalized with COVID-19 [PDF]

, 2022
Remdesivir is the first US Food and Drug Administration (FDA)-approved drug for the treatment of coronavirus disease 2019 (COVID-19). We conducted a retrospective pharmacogenetic study to examine remdesivir-associated liver enzyme elevation among Million
Chanfreau, Catherine, Chang, Kyong-Mi, Chen, Hua-Chang, Chung, Cecilia P., Gorman, Bryan R., Hung, Adriana M., Hunt, Christine M., Joseph, Jacob, Luoh, Shiuh-Wen, Napolioni, Valerio, Robinson-Cohen, Cassianne, Shah, Shailja C., Suzuki, Ayako, Tao, Ran, Tuteja, Sony, VA Million Vet Program COVID-19 Sc, Wendt, Frank, Wilson, Otis, Yu, Zhihong, Zhou, Jin   +19 more
core   +1 more source

Structural Basis for the Inhibition of the RNA-Dependent RNA Polymerase from SARS-CoV-2 by Remdesivir

bioRxiv, 2020
The pandemic of Corona Virus Disease 2019 (COVID-19) caused by SARS-CoV-2 has become a global crisis. The replication of SARS-CoV-2 requires the viral RNA-dependent RNA polymerase (RdRp), a direct target of the antiviral drug, Remdesivir.
W. Yin, C. Mao, X. Luan, D. Shen, Q. Shen, H. Su, Xiao-xi Wang, F. Zhou, Wenfeng Zhao, M. Gao, Shenghai Chang, Yuanchao Xie, Guanghui Tian, He-wei Jiang, S. Tao, Jingshan Shen, Yi Jiang, Hualiang Jiang, Yechun Xu, Shuyang Zhang, Yan Zhang, H. Eric Xu   +21 more
semanticscholar   +1 more source

Repurposing Interleukin-6 Inhibitors to Combat COVID-19. [PDF]

, 2020
Severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) is a pandemic with major implications across the world. One of the most frequent causes of death from SARS-CoV-2 is fatal pneumonia from coronavirus disease 2019 (COVID-19), which is associated
Kato, Shumei, Kurzrock, Razelle
core   +1 more source

High-throughput rational design of the remdesivir binding site in the RdRp of SARS-CoV-2: implications for potential resistance

iScience, 2021
Summary: The use of remdesivir to treat COVID-19 will likely continue before clinical trials are completed. Due to the lengthening pandemic and evolving nature of the virus, predicting potential residues prone to mutation is crucial for the management of
Aditya K. Padhi, Rohit Shukla, Prakash Saudagar, Timir Tripathi   +3 more
doaj   +1 more source

Cytokine release syndrome in COVID-19 patients, a new scenario for an old concern. The fragile balance between infections and autoimmunity [PDF]

, 2020
On 7 January 2020, researchers isolated and sequenced in China from patients with severe pneumonitis a novel coronavirus, then called SARS-CoV-2, which rapidly spread worldwide, becoming a global health emergency.
Diamanti, A. P., Lagana, B., Pioli, C., Rosado, M. M., Sesti, G.   +4 more
core   +2 more sources

Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19: A Randomized Clinical Trial.

Journal of the American Medical Association (JAMA), 2020
Importance Remdesivir demonstrated clinical benefit in a placebo-controlled trial in patients with severe coronavirus disease 2019 (COVID-19), but its effect in patients with moderate disease is unknown.
C. Spinner, R. Gottlieb, G. Criner, J. R. Arribas López, A. Cattelan, A. Soriano Viladomiu, O. Ogbuagu, P. Malhotra, K. Mullane, A. Castagna, L. Chai, M. Roestenberg, O. Tsang, E. Bernasconi, Paul Le Turnier, Shan-Chwen Chang, Devi SenGupta, R. Hyland, A. Osinusi, H. Cao, C. Blair, Hongyuan Wang, A. Gaggar, D. Brainard, M. Mcphail, S. Bhagani, M. Ahn, A. Sanyal, G. Huhn, F. Marty   +29 more
semanticscholar   +1 more source

Combination Therapy With Ensitrelvir and Remdesivir Versus Antiviral Monotherapy in Patients Receiving Anti-CD20 Monoclonal Antibody Therapy: A Retrospective Cohort Study. [PDF]

Cureus
Takano T, Aiba H, Takemura H, Kunishima H.   +3 more
europepmc   +3 more sources

Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency

Journal of Biological Chemistry, 2020
Effective treatments for coronavirus disease 2019 (COVID-19) are urgently needed to control this current pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
Calvin J. Gordon, E. Tchesnokov, E. Woolner, Jason K. Perry, Joy Y. Feng, D. Porter, M. Götte   +6 more
semanticscholar   +1 more source